KLK3 and prostate cancer: PSA screening was associated with increased costs for screening (€214/man), diagnostic work-up (€290/man), treatment for localised prostate cancer (€294/man) and productivity losses (€77/man), with lower costs for treatment for advanced prostate cancer (-€306/man).